Press Releases May 29, 2026 04:30 PM

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion Grants Inducement RSU Awards to New Employees Under Nasdaq Listing Rules

By Sofia Navarro RXRX

Recursion, a clinical stage TechBio company listed on Nasdaq, announced the Compensation Committee's approval of inducement restricted stock units (RSUs) totaling nearly 3 million shares granted to 33 new employees under its 2024 Inducement Equity Incentive Plan. The awards vest over a multi-year schedule and are intended to incentivize employee commencement as permitted by Nasdaq rules.

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
RXRX

Key Points

  • Recursion granted approximately 2.99 million inducement RSUs to 33 new employees as part of its 2024 Inducement Equity Incentive Plan.
  • The RSUs vest quarterly over several years, contingent on continued employment.
  • Recursion leverages advanced machine learning and large-scale experimental processes to innovate in the TechBio and pharmaceutical sectors.

Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).

Each inducement RSU award will vest as to 1/4th of the shares subject to the award on the first quarterly vesting date on or following the one-year anniversary of the vesting commencement date, and as to 1/16th of the shares on each quarterly vesting date thereafter until the inducement RSU award is fully vested, subject to the inducement RSU award recipient’s continued employment through the company vesting dates. Each inducement RSU award is subject to the terms and conditions of the 2024 Plan and the grant agreements covering the awards.

About Recursion

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.

Media Contact
[email protected]

Investor Contact
[email protected]


Risks

  • The inducement RSUs increase shareholder dilution, potentially impacting existing equity value, relevant to investors.
  • The accelerated hiring implied by inducement awards may increase operational costs and raise expectations for revenue growth in the biotech sector.
  • The success of Recursion's platform depends on continued effective integration of AI and biological data, a technological and execution risk.

More from Press Releases

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions Jun 4, 2026 Satellogic to Participate in June Investor Conferences Jun 4, 2026 BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN. BHD. Jun 4, 2026 SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026 Jun 4, 2026 Reliance, Inc. Announces Participation at the Wells Fargo 16th Annual Industrials & Materials Conference Jun 4, 2026